Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group. Rossetti B, et al. Among authors: zazzi m. PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017. PLoS One. 2017. PMID: 29161288 Free PMC article. Clinical Trial.
Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.
De Luca A, Di Giambenedetto S, Romano L, Gonnelli A, Corsi P, Baldari M, Di Pietro M, Menzo S, Francisci D, Almi P, Zazzi M; Antiretroviral Resistance Cohort Analysis Study Group. De Luca A, et al. Among authors: zazzi m. J Infect Dis. 2006 May 1;193(9):1219-22. doi: 10.1086/502976. Epub 2006 Mar 28. J Infect Dis. 2006. PMID: 16586357
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).
Rusconi S, Gianotti N, Adorni F, Boeri E, Menzo S, Gonnelli A, Micheli V, Meraviglia P, Trezzi M, Paolini E, Giacometti A, Corsi P, Di Pietro M, Monno L, Punzi G, Zazzi M; ARCA Collaborative Group. Rusconi S, et al. Among authors: zazzi m. J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):373-5. doi: 10.1097/QAI.0b013e3181378f73. J Acquir Immune Defic Syndr. 2007. PMID: 18090302 No abstract available.
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group. Di Giambenedetto S, et al. Among authors: zazzi m. Antivir Ther. 2009;14(3):359-69. Antivir Ther. 2009. PMID: 19474470
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A. Bracciale L, et al. Among authors: zazzi m. J Antimicrob Chemother. 2009 Sep;64(3):607-15. doi: 10.1093/jac/dkp246. Epub 2009 Jul 16. J Antimicrob Chemother. 2009. PMID: 19608581
326 results